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Abstract
Background: Solvate ionic liquids (SILs) are a new class of ionic liquids that are equimolar solutions of lithium
bistrifluoromethanesulfonimide in either triglyme or tetraglyme, referred to as G3LiTFSA and G4LiTFSA, respectively.
SILs play a role in energy storage lithium batteries, and have been proposed as potential alternatives to traditional
organic solvents such as DMSO. G3TFSA and G4TFSA have been shown to exhibit no toxicity in vivo up to 0.5% (v/
v), and solubilize small compounds (N,N-diethylaminobenzaldehyde) with full penetrance, similar to DMSO
delivered DEAB. Herein, we compare the effects of storage (either at room temperature or − 20 °C) on DEAB
solubilized in either DMSO, G3TFSA or G4TFSA to investigate compound degradation and efficacy.
Results: The findings show that DEAB stored at room temperature (RT) for 4 months solubilized in either G3TFSA,
G4TFSA or DMSO displayed no loss of penetrance. The same was observed with stock solutions stored at − 20 °C
for 4 months; however G4TFSA remained in a liquid state compared to both G3TFSA and DMSO. Moreover, we
examined the ability of G3TFSA and G4TFSA to solubilize another small molecular therapeutic, the FGFR antagonist
SU5402. G4TFSA, unlike G3TFSA solubilized SU5402 and displayed similar phenotypic characteristics and reduced
dlx2a expression as reported and shown with SU5402 in DMSO; albeit more penetrative.
Conclusion: This study validates the use of these ionic liquids as a potential replacement for DMSO in vivo as
organic solubilizing agents.
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Background
In recent years, there has been an increase in the interest
of ionic liquids (ILs) due to their potential in a myriad of
chemical processes. Their unique property of being mol-
ten salts at room temperature imparts unusual properties
such as; high ionic conductivity, non-flammability, and
negligible vapour pressure. Due to these properties, and
their high customisability through anion/cation pairing,
have become a staple material used throughout a variety
of disciplines [1–9]. The use of imidazolium ionic liquids
in drug delivery has seen some success, as they offer the
potential to deliver sparingly soluble molecules via oral, or
transdermal routes over a long period of time [10–17].
Complementing this effect is the conversion of active
pharmaceutical ingredients to ionic liquid-like salts, typic-
ally by inclusion of a charge diffuse cation or anion, which
can result in improved therapeutic effect via changes in
crystal structure [18, 19]. These approaches have largely
revolved around the use of imidazolium-derived ionic liq-
uids which are a well-used and studied class of solvents.
Of particular interest has been a new class of ionic
liquids, termed ‘solvate ionic liquids’ (SILs), reported by
Watanabe et al. [20–26]. The preparation of SILs is
trivial, being simple dissolution of LiNTf2 (lithium
bistrifluoromethanesulfonimide) in either triglyme
(triethylene glycol dimethyl ether, G3) or tetraglyme (tet-
raethylene glycol dimethyl ether, G4) yields the ionic liq-
uids, G3TFSA or G4TFSA, respectively (Fig. 1). Recent
work by our group, and others, has characterised these
solvate ionic liquids using Kamlet-Taft parameters, and
explored their use as a solvent for organic chemical
transformations [27, 28]. Recently, we demonstrated the
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toxicity of solvate ionic liquids in vivo using a zebrafish
(Danio rerio), and found that both G3TFSA and
G4TFSA with concentrations up to 50 μM (or 0.5%) are
not toxic to zebrafish embryos (which are more sensitive
to toxicity than adults) [29]. Since most organic modifier
solvents (such as DMSO) are used at a much lower con-
centration (usually 0.1%), our study was able to conclude
that both G3TFSA and G4TFSA can be safely used as
aqueous modifier solvents to allow evaluation of small
molecules. Both G3TFSA and G4TFSA do not induce
apoptosis at a similar concentration to DMSO (10 μM)
and display a full drug penetrance and the anticipated
physiological changes induced in the test specimens
[29]. Since these novel SILs were able to replace DMSO
as organic modifiers, we were curious if they could be
used as an alternative long term storage media for these
molecules, and if compound degradation over this
period was reduced compared to DMSO.
Currently, the most commonly used organic solvent,
in academic and industrial research laboratories, to
solubilize small organic molecules in water is DMSO
[30]. Due to its ability to dissolve many kinds of com-
pounds, DMSO plays a pivotal role in sample manage-
ment and high-throughput screening during in vivo and
in vitro evaluation.
Due to its broad solubilizing capability and apparent
low toxicity at concentrations < 10%, [31, 32] DMSO is
used as a solvent for many drug types and is used as the
vehicle control of choice for both in vitro and in vivo
studies. However, in a study coordinated by Corderio
et al., the authors demonstrated low-dose toxicity of
DMSO and concluded that solvents other than DMSO
should be employed for solubilizing drugs [33]. Thus
there is a need to find a suitable replacement for DMSO
which do not possess this inherent toxicity.
Therefore, the focus and aim of this study was to
evaluate the performance of the ILs G3TFSA and
G4TFSA as a potential replacement to the conventional
solvent DMSO, using zebrafish as a model organism.
Since, we have shown the ability of G3TFSA and
G4TFSA to solubilize DEAB with full penetrance of
reported phenotypic characteristics [29]; we wanted to
evaluate the impact of storage on both G3TFSA and
G4TFSA, and their ability to solubilize and deliver other
small molecules/pharmacological compounds.
Results
Evaluation of SILs stored at -20 °C
To be consistent with our previous study, which used the
retinoic acid synthesis inhibitor 4-diethylaminobenzaldehyde
(DEAB), we continued to use this molecule as the initial
focus of this work. DEAB is a known inhibitor of retinalde-
hyde dehydrogenases ALDH1A1, ALDH1A2, and
ALDH1A3 in mammals (teleost fish do not have an aldh1a1
gene) [34]. Retinaldehyde dehydrogenases convert retinalde-
hyde, a product from retinol (Vitamin A1), into retinoic acid
(RA) [35]. Hence, inhibiting the function of retinaldehyde
dehydrogenases via DEAB abolishes the synthesis of RA
required for normal growth and development [36]. Thus,
we wanted to evaluate G3TFSA and G4TFSA’s ability to
keep DEAB stable at RT without compound degradation or
loss of efficacy. The rationale behind this test is that stock
solutions kept at RT would remain in a liquid state with no
concern for sample degradation from multiple freeze/thaw
cycles. This was evaluated over a duration of 4 months, and
differences in penetrance of the drug, measured by the
strength of the phenotypes were determined.
To conduct this comparison, N,N-diethylaminobenzal-
dehyde (DEAB), was administered in parallel to zebrafish
embryos: one sample containing DMSO only (0.1%), one
DEAB in DMSO and the other two, containing DEAB in
either G3TFSA or G4TFSA. Zebrafish embryos were
exposed to DEAB in the respective solvents at the begin-
ning of gastrulation occurring at 6 h post fertilization
(hpf ) at a final concentration of 5 μM.
Comparison of the treatments kept at RT showed that
zebrafish embryos exposed to DEAB solubilised in either
DMSO (Fig. 2b), G3TFSA (Fig. 2c), or G4TFSA (Fig. 2d)
from 6 to 30 hpf displayed characteristics associated
with the loss of RA signalling compared to the control
(Fig. 2a): [29, 37, 38] lack of pectoral fin induction
(arrowhead), shortening of the posterior head (marked
by an asterisk) malformation of the otic vesicle (arrow)
and pericardiac oedema. There was no discernible differ-
ences in DEAB penetrance between DEAB in either
Fig. 1 Solvate ionic liquids and DMSO which are the focus of this study
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DMSO, G3TFSA or G4TFSA (100% for each, n = 60)
after storage at RT for 4 months [29].
Evaluation of SILs stored at room temperature
To assess the solvate properties of G3TFSA and
G4TFSA, it was also imperative to evaluate the perform-
ance of the ionic liquids G3TFSA and G4TFSA after
storage in the conventional (frozen) manner. Therefore,
DEAB was stored at − 20 °C for 4 months in either
DMSO, G3TFSA or G4TFSA. A comparison of zebrafish
embryos treated with 5 μM showed that zebrafish em-
bryos exposed to DEAB solubilised in either DMSO
(Fig. 3b), G3TFSA (Fig. 3c), or G4TFSA (Fig. 3d) from 6
to 30 hpf displayed the characteristics associated with
the loss of RA signalling compared to the control
(Fig. 3a) [29, 37, 38] (100% penetrance for all com-
pounds tested, n = 60).
As previously observed in the RT test, there was an
observed phenotype that clearly showed a lack of pec-
toral fin induction (arrowhead), shortening of the poster-
ior head (marked by an asterisk), malformation of the
otic vesicle (arrow) and pericardiac oedema. However,
unlike both DMSO and G3TFSA, G4TFSA did not
freeze at − 20 °C but remained in a viscous state.
Capacity of the SILs to deliver small compounds
With these data in hand, our attention turned to demon-
strating the generality of these ionic liquids as a storage
and delivery media for small molecular therapeutics. For
the purpose of this study, we evaluated the ability of
both G3TFSA and G4TFSA to solubilise and compare
the performance of SU5402 (Fig. 4d) a pan-fibroblast
growth factor receptors (FGFR) specific tyrosine kinase
inhibitor and is used in a multitude of zebrafish develop-
mental systems to specifically inhibit FGFR signalling
against DMSO [39–43]. A comparison of zebrafish em-
bryos treated with both SU5402 in G4TFSA at concen-
trations 2.5 μM (Fig. 4c) and 5 μM (Fig. 4f ) from 6 to 30
hpf displayed previously reported phenotypes, such as
lack of pectoral fin induction (arrowhead) malformation
of the otic vesicle (arrow) compared to the control em-
bryo (Fig. 4a). Embryos treated with SU5402 in DMSO
(Fig. 4b) also reported these phenotypes. There was also
an evident lack of a formed mid-hindbrain boundary at
concentrations of only 5 μM DEAB in DMSO and
G4TFSA (open arrowhead) (Fig. 4e, f ) [38, 44].
Assessing penetrance of the SILs
In addition, we wanted to the examine genes that are
affected by FGF (fibroblast growth factor) signalling.
Hence, we investigated the effect on dlx2a expression
using whole mount in situ hybridisation (WISH) after
exposure to 2.5 μM SU5402 that had been either solubi-
lized in DMSO or G4TFSA (Fig. 5). WISH results
showed that compared to the control embryos (Fig. 5a,
d), embryos treated with SU5402 solubilized in both
DMSO (Fig. 5b, e) and G4TFSA (Fig. 5c, f ) depicted an
absence of dlx2a expression in the ventral cranial neural
crest cells (arrows) marked by an asterix. However,
comparatively there was a greater reduction in the
expression of dlx2a (marked by AP staining) in the tel-
encephalon (arrowhead) in zebrafish embryos that were
treated with SU5402 solubilized in G4TFSA (Fig. 5c, f )
compared to those treated with SU5402 solubilized in
Fig. 2 Room temperature DEAB exposure in developing zebrafish
embryos. Embryos exposed to DEAB at 5 μM in solution at room
temperature for 4 months in either DMSO (b), G3TFSA (c), or G4TFSA
(d) displayed the reported characteristic of loss of RA (compared to
control (DMSO exposed only (a): lack of pectoral fin induction
(arrowhead), shortening of the posterior head (asterisk),
malformation of the otic vesical (arrow) and pericardial edema
Fig. 3 Frozen DEAB exposure in developing zebrafish embryos.
Embryos exposed to DEAB at 5 μM that have been stored for
4 months at -20 °C in either DMSO (b), G3TFSA (c), or G4TFSA (d)
display the reported characteristics of loss of RA (compared to
control (DMSO exposed only (a): lack of pectoral fin induction
(arrowhead), shortening of the posterior head (asterisk),
malformation of the otic vesical (arrow) and pericardial edema
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DMSO (Fig. 5b, e). This indicates that G4TFSA has as
greater ability to deliver SU5402 (penetrative power)
compared to DMSO.
Discussion
Previous studies have shown that the prolonged storage
of organic compounds in solution can lead to significant
sample degradation, and subsequently an increase in the
number of false positives for high-throughput biological
screening assays [45]. These false positives represent po-
tentially erroneous investment of time and money elab-
orating on a false lead compound. As a result, many
researchers and pharmaceutical organizations now store
their organic compounds as frozen DMSO stock
solutions in an environment of low relative humidity, to
mitigate or retard compound degradation [45]. A study
conducted by Kozikowski et al., investigating the effect
of room temperature storage on the stability of com-
pounds in DMSO concluded that the relationship be-
tween length of storage and the probability of observing
the compound is described by a repeated measures
logistic regression model [45]. Results from the study
determined that the probability of observing the com-
pound was 92% after 3 months of storage at room
temperature, 83% after 6 months, and 52% after 1 year
in DMSO [45]. Hence, it is valuable to assess the long
term effects of RT storage on DEAB penetrance post
solubilisation in both G3TFSA and GF4TFSA.
Fig. 4 SU5402 exposure in developing zebrafish embryos. Embryos are exposed to SU5402 (d) at 2.5 μM (b & c) or 5 μM (e & f) in either DMSO
or G4TFSA display the reported characteristics of FGF signaling inhibition compared to control (untreated (a) or DMSO exposed only (b & e)): lack
of pectoral fin induction (marked by an asterisk), malformation of the otic vesicle (arrow). Lloss of MHB (open arrow head) was observed in
embryos treated with 5 μM DEAB. 100× magnification
Fig. 5 Expression of dlx2a visualized using whole mount in situ hybridization. Embryos exposed to SU5402 at 2.5 μM in either DMSO (b & e) or
G4TFSA (c & f) display reduced localization and expression of dlx2a compared to control (DMSO exposed only (a & d) in the hindbrain (arrow)
and in the pharyngeal arches (arrow head, * lack of pharyngeal arches). The first row depicts the embryos in a later orientation, the second row
depicts the embryos in a ventral orientation
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Furthermore, a key characteristic of DMSO is that
compared to G4TFSA it has a relatively higher melting
point (Tm) of around 19 °C [46], hence DMSO freezes
easily and remelts slowly at room temperature. This
means that if stored frozen, a considerable amount of
time will be spent getting DMSO (and the compound
solubilized in DMSO) to a liquid state before it can be
used. Whereas, G4TFSA was able to remain in a liquid
like state at − 20 °C, proving advantageous over DMSO
as it can be used straight away after being removed from
storage at − 20 °C. Similar to DMSO, G3TFSA albeit
higher, has a similar Tm of 23 °C [47]. However, G3TFSA
has a much higher entropy change of fusion value of
112.5 J K− 1 mol− 1 compared to DMSO which only has an
entropy change of fusion value of around 50 J K− 1 mol− 1
[47]. This means that even though both G3TFSA and
DMSO have similar melting temperatures, G3TFSA will
return to a liquid state much quicker than DMSO. Our
10 mL stock of G3TFSA stored at − 20 °C took approxi-
matively 10 min to melt at room temperature (around 20 °
C) while it took slightly over 1 h for the 10 mL stock of
DMSO stored at − 20 °C to completely melt at room
temperature making G3TFSA to return to a liquid state at
least 6 time faster than DMSO.
Consequently, a study looking in to the effect of
freeze/thaw cycles on the stability of compounds in
DMSO concluded that samples that underwent freeze/
thaw cycling suffered the most, showing a drop of more
than 10% in compound efficacy within 10 cycles [48],
and after 25 freeze/thaw cycles tested, the percentage of
compound remaining was 55.8% [48]. Hence, since
G4TFSA does not freeze at -20 °C, there is no risk of
compound degradation due to freeze/thaw cycles.
Moreover, SU5402 was used as a drug of choice in
evaluating the efficacy of the SILs as it is useful for
assessing requirements for FGF signalling in the later
stage of development of the zebrafish embryo because it
can be applied in late developmental events such as
organogenesis, leaving early FGF-dependent processes
unaffected. Additionally, SU5402 treatment potentially
uncovers FGF requirements that are not revealed by
knocking out specific FGF ligands or receptors owing to
redundancy.
In making up the stock solution of SU5402 in the
respective solvents; DMSO, G3TFSA and G4TFSA, it
was observed that SU5402 was not soluble in G3TFSA.
While the structure of both solvate ionic liquids is very
similar, and they possess similar physical properties, the
poly-ether used to fabricate G4TFSA possesses an extra
ethylene unit potentially increasing the solubilising
power of this liquid for small organic molecules [5].
Hence, only SU5402 solubilized in G4TFSA was used to
assess SU5402 phenotypic penetrance against SU5402
solubilized in DMSO.
A previous study by Gibert et al., reported the forma-
tion of oral and pharyngeal dentition in teleosts depends
on differential recruitment of retinoic acid signalling and
that a lack of FGF signalling affects the expression of
dlx2a (distal-less homeobox 2a) [49]. Dlx genes are
expressed in a coordinate manner which create proximal
to distal polarity within the pharyngeal arches [50]. In zeb-
rafish, dlx2a is expressed in the migrating cranial neural
which contributes to the pharyngeal arches [49–53].
In order to get a more accurate understanding into
whether these SILs can be used clinically we will need to
continue our studies in adult and mammalian models.
Even though zebrafish provide an adequate starting
point, the efficacy and penetrance of G3TFSA and
G4TFSA would need to be assessed in a mammalian
model which would share more homology to humans.
Furthermore, by using these models, we could look into
more reported effects known to be caused by these
treatments.
Besides, in order to fully establish whether G3TFSA
and G4TFSA can be used as replacement organic sol-
vents, the efficacy to deliver a wide range of compounds
and therapeutics needs to be assessed. The best way to
do this would be to use an established drug/compound
library which has an established and comprehensive
account of observed side effects and phenotypes.
Conclusions
Our data reveals that both G3TFSA and G4TFSA are
comparable, at least, or slightly superior to DMSO in
terms of compound deliverance as exhibited by the
penetrance of DEAB and SU5402 (the latter only soluble
in both DMSO and G4TFSA). This was evident by
DEAB solubilized in G3TFSA and G4TFSA exhibiting
the same phenotypic characteristics of DEAB made up
in DMSO. SU5402 solubilized in G4TFSA and DMSO,
reduced the expression of dlx2a in zebrafish embryos
although to a greater extent for the latter. However, in
regards to the storage of DEAB stock solutions in
DMSO, G3TFSA and G4TFSA in the more conventional
manner at − 20 °C, G4TFSA remained in a liquid state
as it had a much lower glass-transition temperature, po-
tentially realising a decreased rate of sample degradation.
Consequently, G3TFSA and G4TFSA solubilize and
deliver test/pharmacological compounds adequately and
routinely in research laboratories, hence both G3TFSA
and G4TFSA are suitable replacements for DMSO for
experimental procedures.
Methods
Animal husbandry
Zebrafish were reared and staged at 28.5 °C according to
Kimmel et al. [54] After spawning, embryos were col-
lected and raised in a petri dish in embryonic medium
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E3. As a standard, we raised zebrafish embryos in 30 ml
of E3 with 60 embryos per tube.
Treatments
N,N-Diethylaminobenzaldehyde (DEAB) (Sigma, MO,
USA) and SU5402 (Sigma, MO, USA) were dissolved in
different solvents: DMSO, G3TFSA and G4TFSA at a
concentration of 10 mM. This concentration was chosen
based on our previous published data on the toxicity of
these solvents [29]. Stock solutions on 10 mM were kept
stored in either -20 °C or RT (only DEAB stocks) depend-
ing on the application. After vortexing, appropriate vol-
umes were used to expose zebrafish embryos from 6 to 30
hpf in the dark. Live imaging was performed at 30 hpf.
Whole mount in situ hybridisation
Embryos were fixed in 4% PFA-PBST overnight at 4 °C
and then transferred to and stored in 100% methanol at
-20 °C. Whole-mount in situ hybridization using
digoxigenin-labeled riboprobes was performed as previ-
ously described [49]. Using distal-less homeobox 2a
(dlx2a) as a probe, whole-mount in situ hybridization
was performed on at least 20 embryos (10 treated em-
bryos and 10 control embryos).
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